Bionyra Pharma has launched with an oversubscribed $165 million Series A to advance its clinical-stage pipeline for immune-mediated inflammatory diseases, co-led by Jeito Capital and Sofinnova Partners.
Amount Raised
$165 Million
Round Type
Series A
ParisBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Bionyra Pharma, a clinical-stage biopharmaceutical company, announced its launch with a $165 million oversubscribed Series A financing. The funding was co-led by Jeito Capital and Sofinnova Partners, with participation from several other investors. The company focuses on developing next-generation biologics for autoimmune diseases. Bionyra aims to address the high unmet need for better treatment options in this area.
Quick answer
Bionyra Pharma raised $165 Million in a Series A round, dated June 22, 2026. Investors: Sixty Degree Capital, Sanofi Ventures, Arkin Bio, Apollo Health Ventures, Vives Partners, Jeito Capital and Sofinnova Partners. Bionyra Pharma is based in Paris, Ile-de-France, France.
- How much did Bionyra Pharma raise?
- Bionyra Pharma raised $165 Million in a Series A round on June 22, 2026.
- Who invested in Bionyra Pharma?
- Sixty Degree Capital, Sanofi Ventures, Arkin Bio, Apollo Health Ventures, Vives Partners, Jeito Capital and Sofinnova Partners are named as investors in this round.
- What does Bionyra Pharma do?
- Bionyra Pharma is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for immune-mediated inflammatory diseases.
- Where is Bionyra Pharma based and how big is it?
- Bionyra Pharma is based in Paris, Ile-de-France, France.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Bionyra Pharma that raised within 45 days of this round, from Fundz verified event records.
- Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
- Acasti raised $10M on August 4, 2026.
- Os Therapies raised $1.6M on June 30, 2026.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
- HCW Biologics raised $1.5M (Post-IPO Equity) on July 29, 2026.
- Kaveri Therapeutics raised $1.6M (Seed) on July 21, 2026.
Who to call at Bionyra Pharma, and when
A new round usually means Bionyra Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Bionyra Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bionyra Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bionyra Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bionyra Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansBionyra Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.